ROCKLINC Investment Partners, based in Burlington, offers independent wealth management and value investing strategies for long-term growth.
19 letters, 2015 to 2026
AUM: $1.9B · 13F, Q3 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: RVMD | Current | Biological Products, (No Diagnostic Substances) | COM | 869,256 | -235,954 | -21.3% | 0.40% | $178M | -$29M | 9.59% | $34.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TVTX | Current | Pharmaceutical Preparations | COM | 2,204,085 | +25,016 | +1.1% | 2.30% | $130M | +$6M | 6.98% | $4.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Eli Lilly | NYSE: LLY | Current | Pharmaceutical Preparations | COM | 98,700 | 0 | 0.0% | 0.01% | $114M | -$4M | 6.14% | $1.20T | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: MDGL | Current | Pharmaceutical Preparations | COM | 177,249 | +2,250 | +1.3% | 0.76% | $89M | -$5M | 4.80% | $9.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MIRM | Current | Pharmaceutical Preparations | COM | 779,790 | -18,355 | -2.3% | 1.19% | $67M | -$27M | 3.58% | $6.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RYTM | Current | Pharmaceutical Preparations | COM | 692,598 | 0 | 0.0% | 1.00% | $66M | -$11M | 3.55% | $8.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: KYMR | Current | Biological Products, (No Diagnostic Substances) | COM | 409,631 | -43,525 | -9.6% | 0.48% | $46M | -$6M | 2.46% | $10.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: INSM | Current | Pharmaceutical Preparations | COM PAR $.01 | 365,250 | +3,100 | +0.9% | 0.17% | $42M | +$3M | 2.24% | $31.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: UNH | Current | Hospital & Medical Service Plans | COM | 92,250 | +28,500 | +44.7% | 0.01% | $34M | +$7M | 1.82% | $296B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SRRK | Current | Biological Products, (No Diagnostic Substances) | COM | 682,654 | -32,798 | -4.6% | 0.56% | $33M | -$6M | 1.77% | $6.1B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ASND | Current | Pharmaceutical Preparations | ORD SHS | 144,000 | -24,750 | -14.7% | $33M | -$12M | 1.76% | $16.8B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| NYSE: THC | Current | Services-General Medical & Surgical Hospitals, NEC | COM NEW | 125,000 | 0 | 0.0% | 0.16% | $32M | +$9M | 1.72% | $21.0B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| MiniMed Group, Inc. | Nasdaq: MMED | Current | Surgical & Medical Instruments & Apparatus | COM | 1,605,000 | +85,000 | +5.6% | 0.57% | $31M | +$9M | 1.68% | $4.6B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: IRTC | Current | Surgical & Medical Instruments & Apparatus | COM | 273,950 | +4,300 | +1.6% | 0.81% | $31M | -$0.9M | 1.67% | $3.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ISRG | Current | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM NEW | 72,250 | -4,210 | -5.5% | 0.02% | $29M | -$1M | 1.58% | $138B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ARGX | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADR | 30,000 | -22,750 | -43.1% | $29M | -$20M | 1.55% | $59.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: HTFL | Current | Surgical & Medical Instruments & Apparatus | COM | 575,000 | +1,500 | +0.3% | 0.65% | $29M | +$12M | 1.54% | $3.9B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: DXCM | Current | Surgical & Medical Instruments & Apparatus | COM | 293,500 | -49,500 | -14.4% | 0.08% | $25M | +$2M | 1.36% | $29.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: BSX | Current | Surgical & Medical Instruments & Apparatus | COM | 535,000 | +6,500 | +1.2% | 0.04% | $23M | +$0.8M | 1.26% | $62.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TARS | Current | Biological Products, (No Diagnostic Substances) | COM | 285,122 | +8,035 | +2.9% | 0.58% | $22M | +$5M | 1.21% | $3.8B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AMLX | Current | Pharmaceutical Preparations | COM | 756,774 | +257,010 | +51.4% | 0.59% | $22M | +$13M | 1.18% | $3.4B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CLDX | Current | In Vitro & In Vivo Diagnostic Substances | COM NEW | 653,344 | -45,802 | -6.6% | 0.83% | $21M | -$5M | 1.14% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| agilon health, inc. | NYSE: AGL | Current | Services-Misc Health & Allied Services, NEC | COM NEW | 262,500 | -100 | -0.0% | 1.56% | $21M | -$7M | 1.12% | $1.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ZLAB | Current | Pharmaceutical Preparations | ADR | 791,307 | -23,400 | -2.9% | $21M | +$5M | 1.12% | $2.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ERAS | Current | Pharmaceutical Preparations | COM | 1,405,393 | +3,243 | +0.2% | 0.40% | $21M | -$5M | 1.11% | $5.0B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PHVS | Current | Pharmaceutical Preparations | COM | 648,333 | 0 | 0.0% | $21M | -$2M | 1.11% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: GPCR | Current | Pharmaceutical Preparations | SPONSORED ADS | 640,317 | 0 | 0.0% | 0.30% | $20M | -$14M | 1.08% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ACRS | Current | Pharmaceutical Preparations | COM | 3,791,117 | -539,415 | -12.5% | 2.39% | $20M | -$3M | 1.07% | $555M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: XENE | Current | Pharmaceutical Preparations | COM | 524,758 | -159,149 | -23.3% | 0.53% | $20M | -$22M | 1.05% | $3.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: PEN | Current | Surgical & Medical Instruments & Apparatus | COM | 60,000 | -55,750 | -48.2% | 0.15% | $19M | -$17M | 1.03% | $12.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Avalyn Pharma Inc. | Nasdaq: AVLN | Current | Pharmaceutical Preparations | COM SHS | 662,918 | 0 | 0.0% | 1.50% | $19M | -$3M | 1.02% | $1.3B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: PBLS | Current | Pharmaceutical Preparations | COM | 577,281 | -747 | -0.1% | $19M | +$3M | 1.00% | $3.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: NBIX | Current | Biological Products, (No Diagnostic Substances) | COM | 130,500 | -14,250 | -9.8% | 0.13% | $19M | -$6M | 1.00% | $15.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ELVN | Current | Pharmaceutical Preparations | COM | 393,659 | -70,966 | -15.3% | 0.53% | $18M | -$6M | 0.97% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Hemab Therapeutics Holdings, Inc. | Nasdaq: COAG | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 575,432 | 0 | 0.0% | 1.23% | $18M | -$3M | 0.95% | $1.9B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| NYSE: INSP | Current | Surgical & Medical Instruments & Apparatus | COM | 244,000 | 0 | 0.0% | 0.84% | $17M | +$6M | 0.91% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: DHR | Current | Industrial Instruments For Measurement, Display, and Control | COM | 76,300 | 0 | 0.0% | 0.01% | $17M | +$2M | 0.91% | $155B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| MBX Biosciences, Inc. | Nasdaq: MBX | Current | Pharmaceutical Preparations | COM | 275,347 | -22,871 | -7.7% | 0.55% | $16M | -$0.3M | 0.87% | $2.7B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| OMEROS CORP | Nasdaq: OMER | Current | Pharmaceutical Preparations | COM | 847,206 | +128,707 | +17.9% | 1.14% | $16M | +$9M | 0.87% | $1.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: AGIO | Current | Pharmaceutical Preparations | COM | 472,335 | -60,228 | -11.3% | 0.79% | $16M | -$4M | 0.84% | $1.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Newamsterdam Pharma Company | Current | ORDINARY SHARES | 613,942 | +31,198 | +5.4% | $15M | -$5M | 0.80% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: DYN | Current | Pharmaceutical Preparations | COM | 891,869 | -50,285 | -5.3% | 0.48% | $14M | -$7M | 0.77% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RARE | Current | Pharmaceutical Preparations | COM | 925,089 | -42,766 | -4.4% | 0.91% | $14M | -$18M | 0.75% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ZBIO | Current | Pharmaceutical Preparations | COM | 502,077 | 0 | 0.0% | 0.74% | $14M | +$0.8M | 0.73% | $1.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CAI | Current | Services-Medical Laboratories | COM | 438,500 | -49,000 | -10.1% | 0.15% | $13M | +$5M | 0.72% | $5.3B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CYTK | Current | Pharmaceutical Preparations | COM NEW | 201,839 | +13,859 | +7.4% | 0.14% | $13M | -$3M | 0.72% | $7.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BBIO | Current | Pharmaceutical Preparations | COM | 192,250 | +47,500 | +32.8% | 0.10% | $13M | +$2M | 0.68% | $15.2B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: COGT | Current | Pharmaceutical Preparations | COM | 389,363 | -126,554 | -24.5% | 0.22% | $12M | -$7M | 0.67% | $4.8B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MLYS | Current | Pharmaceutical Preparations | COM | 484,951 | 0 | 0.0% | 0.55% | $12M | -$0.9M | 0.66% | $1.3B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SMMT | Current | Pharmaceutical Preparations | COM | 715,000 | 0 | 0.0% | 0.09% | $12M | +$2M | 0.65% | $8.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Vera Therapeutics, Inc. | Nasdaq: VERA | Current | Pharmaceutical Preparations | CL A | 356,206 | -71,378 | -16.7% | 0.49% | $12M | -$7M | 0.62% | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: TNGX | Current | Pharmaceutical Preparations | COM | 460,031 | +3,480 | +0.8% | 0.27% | $11M | -$3M | 0.62% | $3.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Latigo Biotherapeutics, Inc. | Nasdaq: LTGO | Current | Pharmaceutical Preparations | COM | 654,497 | +654,497 | New | 0.99% | $11M | +$11M | 0.59% | $878M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: PTCT | Current | Pharmaceutical Preparations | COM | 166,548 | +4,250 | +2.6% | 0.20% | $11M | -$2M | 0.58% | $4.9B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FRNM | Current | Services-Medical Laboratories | COMMON STOCK | 677,220 | +677,220 | New | 0.61% | $11M | +$11M | 0.57% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: BCAX | Current | Pharmaceutical Preparations | COM | 535,286 | 0 | 0.0% | 0.81% | $10M | -$6M | 0.54% | $605M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALNY | Current | Pharmaceutical Preparations | COM | 38,000 | -28,750 | -43.1% | 0.03% | $9M | -$11M | 0.50% | $19.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SUPN | Current | Pharmaceutical Preparations | COM | 256,500 | +11,000 | +4.5% | 0.22% | $9M | -$0.9M | 0.49% | $1.7B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: SYK | Current | Surgical & Medical Instruments & Apparatus | COM | 32,300 | +3,300 | +11.4% | 0.01% | $9M | -$0.2M | 0.48% | $118B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Evolent Health, Inc. | NYSE: EVH | Current | Services-Management Services | CL A | 2,380,000 | -120,000 | -4.8% | 2.10% | $8M | -$5M | 0.45% | $388M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CORT | Current | Pharmaceutical Preparations | COM | 72,000 | 0 | 0.0% | 0.07% | $8M | +$2M | 0.45% | $7.1B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ARDX | Current | Pharmaceutical Preparations | COM | 2,369,869 | +128,100 | +5.7% | 0.94% | $8M | -$3M | 0.44% | $769M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALKS | Current | Pharmaceutical Preparations | SHS | 199,811 | 0 | 0.0% | 0.12% | $8M | -$2M | 0.44% | $7.8B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IMNM | Current | Pharmaceutical Preparations | COM | 367,354 | +19,688 | +5.7% | 0.31% | $8M | +$0.5M | 0.42% | $2.0B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: PHR | Current | Services-Business Services, NEC | COM | 748,500 | +51,600 | +7.4% | 1.21% | $8M | +$0.6M | 0.42% | $737M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Azenta, Inc. | Nasdaq: AZTA | Current | Special Industry Machinery, NEC | COM | 202,750 | -200,250 | -49.7% | 0.46% | $7M | -$3M | 0.38% | $2.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| NYSE: TMO | Current | Measuring & Controlling Devices, NEC | COM | 10,000 | 0 | 0.0% | <0.01% | $7M | +$2M | 0.36% | $248B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| EDAP TMS SA | Nasdaq: FOCL | Current | Electromedical & Electrotherapeutic Apparatus | SPONSORED ADR | 1,450,000 | +64,000 | +4.6% | 3.07% | $6M | -$0.7M | 0.35% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: JANX | Current | Pharmaceutical Preparations | COM | 367,009 | 0 | 0.0% | 0.60% | $6M | +$0.7M | 0.34% | $630M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: DFTX | Current | Medicinal Chemicals & Botanical Products | COM SHS | 154,188 | +11,001 | +7.7% | 0.11% | $6M | -$0.9M | 0.32% | $4.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: OMDA | Current | Services-Health Services | COM | 260,250 | -112,750 | -30.2% | 0.42% | $5M | -$3M | 0.29% | $775M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Spyre Therapeutics, Inc. | Nasdaq: SYRE | Current | Pharmaceutical Preparations | COM NEW | 57,546 | +15,292 | +36.2% | 0.06% | $5M | +$1M | 0.28% | $9.3B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Neurogene Inc. | Nasdaq: NGNE | Current | Pharmaceutical Preparations | COM | 154,401 | +47,651 | +44.6% | 0.75% | $4M | +$0.9M | 0.23% | $475M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 |
| NYSE: NVO | Current | Pharmaceutical Preparations | ADR | 110,800 | +47,300 | +74.5% | $4M | +$1M | 0.23% | $171B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: TLPH | Current | Pharmaceutical Preparations | COM NEW | 3,589,186 | 0 | 0.0% | 6.91% | $4M | +$0.5M | 0.22% | $38M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| AbCellera Biologics Inc. | Nasdaq: ABCL | Current | Pharmaceutical Preparations | COM | 275,000 | +275,000 | New | 0.08% | $4M | +$4M | 0.22% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Mobia Medical, Inc. | Nasdaq: MOBI | Current | Surgical & Medical Instruments & Apparatus | COMMON STOCK | 418,200 | 0 | 0.0% | 1.25% | $4M | -$2M | 0.21% | $395M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Alphatec Holdings, Inc. | Nasdaq: ATEC | Current | Surgical & Medical Instruments & Apparatus | COM NEW | 360,900 | +900 | +0.3% | 0.23% | $4M | +$0.6M | 0.20% | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Trevi Therapeutics, Inc. | Nasdaq: TRVI | Current | Pharmaceutical Preparations | COM | 260,000 | 0 | 0.0% | 0.18% | $4M | -$1M | 0.20% | $2.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ROIV | Current | Pharmaceutical Preparations | SHS | 101,250 | +250 | +0.2% | 0.01% | $4M | +$0.1M | 0.20% | $28.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CMPX | Current | Biological Products, (No Diagnostic Substances) | COM | 3,524,929 | 0 | 0.0% | 1.96% | $4M | -$4M | 0.20% | $122M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PCVX | Current | Biological Products, (No Diagnostic Substances) | COM | 60,250 | 0 | 0.0% | 0.04% | $3M | -$0.1M | 0.18% | $9.2B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: OLMA | Current | Pharmaceutical Preparations | COM | 383,578 | +148,400 | +63.1% | 0.44% | $3M | +$0.4M | 0.18% | $626M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SGMT | Current | Pharmaceutical Preparations | COM SER A | 315,458 | +65,458 | +26.2% | $3M | +$1M | 0.17% | $692M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| NYSE: RCUS | Current | Pharmaceutical Preparations | COM | 114,654 | -65,346 | -36.3% | 0.08% | $3M | -$3M | 0.16% | $2.3B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| OCULAR THERAPEUTIX, INC | Nasdaq: OCUL | Current | Pharmaceutical Preparations | COM | 383,716 | 0 | 0.0% | 0.17% | $3M | -$0.8M | 0.16% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: IONS | Current | Pharmaceutical Preparations | COM | 65,500 | +65,500 | New | 0.04% | $3M | +$3M | 0.16% | $4.5B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IMVT | Current | Biological Products, (No Diagnostic Substances) | COM | 70,103 | +70,103 | New | 0.03% | $2M | +$2M | 0.13% | $6.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NERVGEN PHARMA CORP. | Nasdaq: NGEN | Current | Pharmaceutical Preparations | COM | 1,208,231 | 0 | 0.0% | $2M | -$0.2M | 0.12% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Atea Pharmaceuticals, Inc. | Nasdaq: AVIR | Current | Pharmaceutical Preparations | COM | 433,620 | +433,620 | New | 0.54% | $2M | +$2M | 0.12% | $316M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: IPSC | Current | Biological Products, (No Diagnostic Substances) | COM | 1,304,347 | 0 | 0.0% | 0.72% | $2M | -$1.0M | 0.12% | $240M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: CVS | Current | Retail-Drug Stores and Proprietary Stores | COM | 25,500 | -14,500 | -36.3% | <0.01% | $2M | -$2M | 0.12% | $102B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CELC | Current | Services-Medical Laboratories | COM | 25,513 | +25,513 | New | 0.05% | $2M | +$2M | 0.11% | $2.8B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CLYM | Current | Pharmaceutical Preparations | COM | 116,461 | +116,461 | New | 0.20% | $1M | +$1M | 0.07% | $545M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: HUM | Current | Hospital & Medical Service Plans | COM | 3,350 | +3,350 | New | <0.01% | $1M | +$1M | 0.07% | $45.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Braveheart Bio, Inc. | Nasdaq: BRVE | Current | Pharmaceutical Preparations | COM SHS | 60,837 | +60,837 | New | 0.07% | $1M | +$1M | 0.07% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| EyePoint, Inc. | Nasdaq: EYPT | Current | Laboratory Analytical Instruments | COM NEW | 329,170 | +60,651 | +22.6% | 0.29% | $1M | -$3M | 0.06% | $30M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: AXSM | Current | Pharmaceutical Preparations | COM | 5,500 | 0 | 0.0% | 0.01% | $1M | -$0.3M | 0.05% | $7.1B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LENZ | Current | Biological Products, (No Diagnostic Substances) | COM | 257,460 | 0 | 0.0% | 0.82% | $1.0M | -$0.5M | 0.05% | $105M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Exact Sciences Corp | Exited | COM | 0 | -601,800 | -100.0% | -$61M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Merus N V | Exited | COM | 0 | -597,051 | -100.0% | -$56M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: FRPT | Exited | Grain Mill Products | COM | 0 | -327,500 | -100.0% | -$49M | $3.2B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Cidara Therapeutics, Inc. | Exited | COM NEW | 0 | -204,878 | -100.0% | -$45M | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Ascendis Pharma A/S Sponsored ADR | Exited | SPONSORED ADR | 0 | -194,000 | -100.0% | -$44M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: PODD | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -114,250 | -100.0% | -$30M | $9.5B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Akero Therapeutics Inc | Exited | COM | 0 | -626,526 | -100.0% | -$30M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: ALGN | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 0 | -114,500 | -100.0% | -$29M | $11.3B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Blueprint Medicines Corp | Exited | COM | 0 | -185,500 | -100.0% | -$24M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Arcellx | Exited | COMMON STOCK | 0 | -169,859 | -100.0% | -$20M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| LifeStance Health Group, Inc. | Nasdaq: LFST | Exited | Services-Health Services | COM | 0 | -2,550,000 | -100.0% | -$19M | $5.1B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Warby Parker Inc. | NYSE: WRBY | Exited | Ophthalmic Goods | CL A COM | 0 | -835,000 | -100.0% | -$15M | $3.0B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Crinetics Pharmaceuticals Inc | Exited | COM | 0 | -294,100 | -100.0% | -$15M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| NYSE: OSCR | Exited | Hospital & Medical Service Plans | CL A | 0 | -700,000 | -100.0% | -$15M | $8.1B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Centessa Pharmaceuticals PLC | Exited | SPONSORED ADS | 0 | -351,828 | -100.0% | -$14M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: JNJ | Exited | Pharmaceutical Preparations | COM | 0 | -80,000 | -100.0% | -$13M | $643B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Springworks Therapeutics Inc | Exited | COM | 0 | -328,911 | -100.0% | -$12M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: BMRN | Exited | Pharmaceutical Preparations | COM | 0 | -151,000 | -100.0% | -$11M | $11.9B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: KRYS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -55,861 | -100.0% | -$10M | $9.4B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: NMRA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -955,106 | -100.0% | -$10M | $65M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: MREO | Exited | Pharmaceutical Preparations | SPON ADS | 0 | -4,570,649 | -100.0% | -$9M | $44M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: XNCR | Exited | Pharmaceutical Preparations | COM | 0 | -401,013 | -100.0% | -$9M | $2.6B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Aurinia Pharmaceuticals Inc. | Nasdaq: AUPH | Exited | Pharmaceutical Preparations | COM | 0 | -1,179,740 | -100.0% | -$9M | $2.0B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Soleno Therapeutics Inc | Exited | COM | 0 | -257,253 | -100.0% | -$9M | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| REGENERON PHARMACEUTICALS, INC. | Nasdaq: REGN | Exited | Pharmaceutical Preparations | COM | 0 | -10,100 | -100.0% | -$8M | $95.5B | Q2 2026 | 14 Aug 2026 | Q1 2025 | Q1 2026 | 13F, Q1 2026 | |||
| RAPT Therapeutics | Exited | COM NEW | 0 | -213,731 | -100.0% | -$7M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nuvalent Inc | Exited | COM | 0 | -93,328 | -100.0% | -$7M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Dynavax Technologies | Exited | COM NEW | 0 | -605,013 | -100.0% | -$7M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Apellis Pharmaceuticals Inc | Exited | COM | 0 | -162,750 | -100.0% | -$7M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Pacira BioSciences, Inc. | Nasdaq: PCRX | Exited | Pharmaceutical Preparations | COM | 0 | -400,000 | -100.0% | -$6M | $1.5B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Terns Pharmaceuticals Inc | Exited | COM | 0 | -113,748 | -100.0% | -$6M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: CGEM | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -668,233 | -100.0% | -$5M | $589M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: BHVN | Exited | Pharmaceutical Preparations | COM | 0 | -129,858 | -100.0% | -$5M | $2.1B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nevro Corp | Exited | COM | 0 | -800,494 | -100.0% | -$5M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Mersana Therapeutics Inc | Exited | COM | 0 | -152,586 | -100.0% | -$4M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Essa Pharma Inc | Exited | COM NEW | 0 | -677,005 | -100.0% | -$4M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Theravance Biopharma Inc | Exited | COM | 0 | -208,771 | -100.0% | -$4M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Spdr Series Trust | Exited | Fund | STATE STREET SPD | 0 | -30,000 | -100.0% | -$4M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | |||||
| Indivior PLC | Exited | ORD | 0 | -105,100 | -100.0% | -$4M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| CYPHERPUNK TECHNOLOGIES INC. | Nasdaq: CYPH | Exited | Finance Services | COM NEW | 0 | -1,266,546 | -100.0% | -$4M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Kestra Medical Technologies Ltd. | Exited | SHS | 0 | -145,000 | -100.0% | -$4M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||||
| Acumen Pharmaceuticals, Inc. | Nasdaq: ABOS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,838,916 | -100.0% | -$3M | $14M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Inozyme Pharma Inc | Exited | COM | 0 | -3,445,299 | -100.0% | -$3M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: BEAM | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -150,020 | -100.0% | -$3M | $2.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Xilio Therapeutics, Inc. | Nasdaq: XLO | Exited | Pharmaceutical Preparations | COM | 0 | -3,003,259 | -100.0% | -$3M | $3M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| NYSE: WST | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -9,750 | -100.0% | -$3M | $27.6B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Autolus Therapeutics plc | Nasdaq: AUTL | Exited | Biological Products, (No Diagnostic Substances) | SPON ADS | 0 | -1,032,988 | -100.0% | -$2M | $261M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| NYSE: MDT | Exited | Electromedical & Electrotherapeutic Apparatus | SHS | 0 | -30,900 | -100.0% | -$2M | $129B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: EW | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 0 | -28,900 | -100.0% | -$2M | $59.7B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Teva Pharmaceutical Inds Ltd | Exited | SPONSORED ADS | 0 | -59,000 | -100.0% | -$2M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||||
| Dianthus Therapeutics, Inc. /DE/ | Nasdaq: DNTH | Exited | Pharmaceutical Preparations | COM | 0 | -20,326 | -100.0% | -$2M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Biomea Fusion, Inc. | Nasdaq: BMEA | Exited | Pharmaceutical Preparations | COM | 0 | -181,147 | -100.0% | -$2M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: ACHC | Exited | Services-Specialty Outpatient Facilities, NEC | COM | 0 | -75,500 | -100.0% | -$2M | $3.2B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Korro Bio, Inc. | Nasdaq: KRRO | Exited | Pharmaceutical Preparations | COM | 0 | -35,719 | -100.0% | -$2M | $167M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: LUNG | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -651,100 | -100.0% | -$2M | $119M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Perspective Therapeutics, Inc. | NYSE: CATX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -444,383 | -100.0% | -$2M | $95M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| MACROGENICS INC | Nasdaq: MGNX | Exited | Pharmaceutical Preparations | COM | 0 | -1,145,214 | -100.0% | -$1M | $127M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: ALT | Exited | Pharmaceutical Preparations | COM NEW | 0 | -471,465 | -100.0% | -$1M | $274M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: SGRY | Exited | Services-General Medical & Surgical Hospitals, NEC | COM | 0 | -84,000 | -100.0% | -$1M | $3.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Allakos Inc | Exited | COM | 0 | -1,100,409 | -100.0% | -$1M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Applied Therapeutics Inc | Exited | COM | 0 | -2,075,991 | -100.0% | -$1M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: SRPT | Exited | Pharmaceutical Preparations | COM | 0 | -68,600 | -100.0% | -$1M | $1.5B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: MLTX | Exited | Pharmaceutical Preparations | CLASS A ORD | 0 | -61,700 | -100.0% | -$1M | $939M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: ORKA | Exited | Pharmaceutical Preparations | COM | 0 | -12,051 | -100.0% | -$1M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | |||||
| Nasdaq: JAZZ | Exited | Pharmaceutical Preparations | SHS USD | 0 | -5,750 | -100.0% | -$1M | $15.2B | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: VKTX | Exited | Pharmaceutical Preparations | COM | 0 | -25,500 | -100.0% | -$1.0M | $3.3B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Vigil Neuroscience Inc | Exited | COM | 0 | -471,958 | -100.0% | -$0.8M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: PLRX | Exited | Pharmaceutical Preparations | COM | 0 | -589,996 | -100.0% | -$0.8M | $38M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| SPRUCE BIOSCIENCES, INC. | Nasdaq: SPRB | Exited | Pharmaceutical Preparations | COM | 0 | -2,609,125 | -100.0% | -$0.8M | $116M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| OTC: ADAPY | Exited | Biological Products, (No Diagnostic Substances) | SPONDS ADS | 0 | -2,483,468 | -100.0% | -$0.6M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||||
| Gossamer Bio Inc | Exited | COM | 0 | -1,609,492 | -100.0% | -$0.5M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: CRL | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -2,700 | -100.0% | -$0.4M | $15.7B | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| 89bio Inc | Exited | COM | 0 | -40,000 | -100.0% | -$0.4M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: NVAX | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -45,000 | -100.0% | -$0.4M | $1.3B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Amicus Therapeutic | Exited | COM | 0 | -21,062 | -100.0% | -$0.3M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Prothena Corp PLC | Exited | SHS | 0 | -25,398 | -100.0% | -$0.2M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| NYSE: NUVB | Exited | Pharmaceutical Preparations | *W EXP 02/10/202 | 0 | -134,028 | -100.0% | -$0.0M | $1.3B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: CGEN | Exited | Biological Products, (No Diagnostic Substances) | ORD | 0 | -13,430 | -100.0% | -$0.0M | $178M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 |